Pre-approval Information Exchange Act of 2022
Summary
Pre-approval Information Exchange Act of 2022 This bill specifies that economic, scientific, or other product support information that is exchanged between drug manufacturers and health care entities (e.g., pharmacy benefit managers) about drug products before regulatory approval is not considered to be misbranding or prohibited premarket promotion if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
Bill status
in committee
1 of 4 stages cleared
Introduction
Mar 2022
Committee Review
Floor Vote
President
Introduced Mar 9, 2022
Last action Mar 10, 2022
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Mar 10, 2022
Committee
Referred to the Subcommittee on Health.
lower
Mar 9, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Mar 9, 2022
Introduced
Introduced in House
lower
1 primary · 1 co-sponsor
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 7008
Scope: US
Hi! I can help you understand HR 7008. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline